CR Intrinsic Investors is one of SAC Capital's subsidiaries, and one of its foci is on the biopharmaceutical industry. CR Intrinsic has previously employed Mathew Martoma, a portfolio manager who was charged with insider trading by the SEC earlier this year. CR Intrinsic's $600 million settlement was the largest of its kind on record. The fund has an estimated $2 billion to $3 billion in assets under management.
Hedge Fund - CR Intrinsic Investors
Get Email AlertsSac Subsidiary Bio, Returns, AUM, Net Worth

Fund Profile
Filing Period:
Fund Name: | CR Intrinsic Investors |
Manager | Sac Subsidiary |
Portfolio Value | $0 |
Change This QTR | 0.00% |
News, Interviews and Investor Letters